Literature DB >> 7923461

Anti-idiotype antibodies and circulating immune complexes after immunisation with tetanus-toxoid.

P S Kamath1, S S Badakere, B C Mehta.   

Abstract

OBJECTIVES: To determine if anti-idiotype antibodies and circulating immune complexes in individuals before and after immunisation with tetanus toxoid play a role in the immune response.
DESIGN: A study of individuals who were administered a single dose of tetanus toxoid (TT) and who were unimmunized.
SETTING: Out patient departments of a large public hospital in Bombay, India.
SUBJECTS: Thirty eight individuals pre-immunisation and forty five individuals post-immunisation with tetanus toxoid, tested at 1, 3, 6, and 12 months. MAIN OUTCOME MEASURE: Development of anti-tetanus anti-idiotype antibodies and circulating immune complexes.
RESULTS: Pre-immunisation cases did show presence of anti-tetanus antibodies but in lower titres than post-immunisation up to six months, after which there was a reduction. Specific anti-idiotype antibodies were detected in 19 cases. One and three months after immunisation more cases had high titre antibodies and circulating immune complexes, though after six months, there was a fall in anti-tetanus antibody titres. Circulating immune complexes were seen in those samples having anti-idiotype antibodies.
CONCLUSIONS: Though a significant rise in anti-tetanus antibody anti-idiotype antibodies, protective levels in mice and circulating immune complexes are seen after immunisation with TT it lasts for six months. When followed up for a period of one year it is observed that in cases having auto anti-idiotype antibodies, the anti-tetanus antibodies are maintained for a longer period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923461

Source DB:  PubMed          Journal:  Ceylon Med J        ISSN: 0009-0875


  2 in total

1.  Anti-idiotype antibodies in immune regulation of anca associated vasculitis.

Authors:  Vandana D Pradhan; Kanjaksha Ghosh
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

Review 2.  Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?

Authors:  Rossella Talotta; Erle S Robertson
Journal:  Cytokine Growth Factor Rev       Date:  2021-05-28       Impact factor: 7.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.